Ambry Genetics and Prominent Oncology Research Collaborators to Share New Hereditary Cancer Data at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Key authors to discuss research on HER2-positive breast cancer with CHEK2 mutations, triple negative breast cancer risk among >12 hereditary breast cancer genes and risk for hereditary cancer faced by men with prostate cancer

Ambry’s SuperLab furthers commitment to innovative product development impacting clinical care, leading to the announcement of improved hereditary cancer testing options

Aliso Viejo, CA – June 1, 2016 – Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, today announced four accepted external and internal scientific abstracts to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL June 3-7, 2016. Additionally, two Ambry abstracts have been accepted to be published in a Journal of Clinical Oncology supplement. Ambry has partnered with its collaborators to make key authors available at the Ambry conference booth (#2097) to discuss their research and field questions.

These events underscore Ambry’s unwavering dedication to scientific collaboration and data sharing, which is also emphasized through its AmbryShare program. Through this initiative, Ambry offers its rapidly growing database of anonymized aggregated genomic data (variant frequencies) from whole exome sequencing – initially focused on patients with breast and/or ovarian cancer – to fulfill the promise of the human genome to understand all human disease.

Jill S. Dolinsky, RN, MS, CGC, Senior Manager of Clinical Research at Ambry and abstract co-author offered, “We are honored to be engaged in collaboration with highly respected hereditary cancer researchers and present results from this work at the 2016 ASCO Annual Meeting. Our abstracts and events emphasize our rich dedication to data sharing and partnering with colleagues to further our collective understanding of hereditary cancer risks.”

ASCO Poster Session Abstracts
(three of four listed here; all on Monday June 6, 8-11:30am at Hall A):

Risks of triple negative breast cancer associated with cancer predisposition gene mutations. (Abstract #1513)
Fergus Couch, PhD, et al.
Mayo Clinic
Selected for ASCO Poster Discussion Session: Monday June 6, 1:15-2:30pm at S404
Available at Ambry booth (#2097) Sunday June 5, 12-1pm*

Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer. (Abstract #1539)
Chethan Ramamurthy, MD and Elias Obeid, MD, MPH, et al.
Fox Chase Cancer Center
Available at Ambry booth (#2097) Saturday June 4, 11am-12pm*

Gender bias: underdiagnosing hereditary cancer in men with prostate cancer. (Abstract #1545)
Lauren Bowling, MS, CGC, et al.
Ambry Genetics
Available at Ambry booth (#2097) Saturday June 4, 12-1pm*

Chosen for inclusion online in the 2016 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement:

Exploring trends in mutation distribution of MGPT based on ethnicity. (Abstract #e13112)
Laura Panos, MS, CGC, et al.
Ambry Genetics
J Clin Oncol. 34, 2016 (suppl; abstr e13112)

PALB2 mutation carriers: Are clinicians acting on the molecular diagnosis? (Abstract #13121)
Virginia Speare, PhD, CGC, et al.
Ambry Genetics
J Clin Oncol. 34, 2016 (suppl; abstr e13121)

*Not an official event of the 2016 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation. Not CME-accredited.

For details about all of Ambry’s ASCO abstracts and ongoing research efforts, please visit here.

Ambry also announces many improvements to its hereditary cancer testing menu, all made possible because of the company’s fully-automated SuperLab. This new lab allows for increased efficiency while maintaining superior quality across all product lines.

Ambry’s Senior Director of Clinical Operations, Sharon Mexal PhD, stated, “Ambry designed every workflow detail of our new lab around the most efficient patient testing, while enhancing upon our already robust quality standards. We are excited to be opening our doors to faster turnaround times on our comprehensive offerings.”

As of today, the following hereditary cancer testing updates are available:

  • Faster turnaround times:
    • BRCA1/BRCA2 analysis: 6-10 calendar days
    • All multi-gene hereditary cancer panels: 14-21 calendar days or lower
  • Gene additions: BRIP1, PALB2, RAD51C and RAD51D to GYNplusTM, a panel for hereditary ovarian and/or uterine cancer 

For more details about Ambry’s SuperLab and other updates to Ambry’s testing services, please visit here.


About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Corporate Communications Manager
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...